Unity Biotechnology Faces Nasdaq Delisting Notice

The latest announcement is out from Unity Biotechnology ( (UBX) ).

On June 18, 2025, Unity Biotechnology received a notification from Nasdaq regarding its common stock’s closing bid price being below $1.00 per share for 30 consecutive business days, which is below the minimum requirement for continued listing. The company has until December 15, 2025, to regain compliance, with potential for an additional compliance period if certain conditions are met. Previously, on March 14, 2025, Unity Biotechnology was also notified of its stockholders’ equity falling below the required $10,000,000, and it submitted a compliance plan to Nasdaq. The company is exploring measures to regain compliance, but there is no assurance of success, and its stock may face delisting.

The most recent analyst rating on (UBX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Unity Biotechnology stock, see the UBX Stock Forecast page.

Spark’s Take on UBX Stock

According to Spark, TipRanks’ AI Analyst, UBX is a Underperform.

Unity Biotechnology’s overall score is weighed down by significant financial challenges, including persistent losses and negative equity. Technical analysis suggests a bearish trend with limited momentum. Valuation metrics reflect the unprofitability of the company. However, the recent strategic appointment to the Board provides a potential strategic advantage in its program development.

To see Spark’s full report on UBX stock, click here.

More about Unity Biotechnology

Unity Biotechnology, Inc. operates in the biotechnology industry, focusing on developing therapeutics to extend healthspan by slowing, halting, or reversing diseases of aging.

Average Trading Volume: 310,297

Technical Sentiment Signal: Sell

Current Market Cap: $13.6M

For detailed information about UBX stock, go to TipRanks’ Stock Analysis page.